Q-omics provides the consensus-scored LTC4S profile across patient tissues and cancer cell-line models. LTC4S expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, LTC4S is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, LTC4S RNA expression shows 16,015 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight PAAD, and LUAD as cancer lineages where LTC4S shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LTC4S — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LTC4S survival associations across molecular data types. LTC4S RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LTC4S RNA expression–survival associations across cancer types. High LTC4S expression shows unfavorable associations in DLBC, but favorable associations in PAAD, KIRC, SKCM, SARC and LIHC. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for LTC4S RNA expression.
This table summarizes LTC4S tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for LTC4S. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LTC4S shows lower tumor expression in LUAD, UCEC, LUSC, KICH, STAD and BRCA. The LUAD box plot shows higher LTC4S RNA expression in normal versus tumor tissue (log2 FC = −0.291, t-test p < 0.001).
This table shows molecular features associated with LTC4S in patient tissues and cancer cell lines. In patient samples, LTC4S shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, LTC4S RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
